LINC00978 Promotes Hepatocellular Carcinoma Carcinogenesis Partly Via Activating the MAPK/ERK Pathway

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2020 Feb 21

PMID 32077915

Citations 11

Authors

Quan Zhang

Shujie Cheng

Liye Cao

Jihong Yang

Yu Wang

Yaqing Chen

Affiliations

Soon will be listed here.

Abstract

Objective: To study the role of long non-coding RNA (lncRNA) LINC00978 in hepatocellular carcinoma (HCC) carcinogenesis.

Materials And Methods: LINC00978 expression level was measured by reverse transcription quantitative real-time PCR (RT-qPCR) in HCC tissues and adjacent healthy liver tissues from 49 HCC patients. MTT assay, colony forming assay, and flow cytometry were performed to evaluate the effects of shRNA-mediated LINC00978 knockdown on HCC cell proliferation, cell cycle progression, and apoptosis in vitro. Xenograft tumor model was performed to determine the effects of LINC00978 knockdown on HCC tumor growth in vivo. Western blot was used to assess the activation of signaling molecules in the apoptosis and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway.

Results: LINC00978 expression was significantly up-regulated in human HCC tissue relative to adjacent normal tissue, and LINC00978 high expression was correlated with poor HCC overall survival. LINC00978 was up-regulated in HCC cell lines. ShRNA-mediated LINC00978 knockdown significantly decreased HCC cell proliferation, and induced HCC cell cycle arrest and apoptosis in vitro. LINC00978 knockdown led to significant decrease in tumor xenograft size in vivo. Western blots revealed LINC00978 inhibition decreased ERK, p38, and c-Jun N-terminal kinase (JNK) phosphorylation in HCC cells.

Conclusions: LINC00978 is highly expressed in human HCC tissue and correlates with poor HCC prognosis. LINC00978 promotes HCC cell proliferation, cell cycle progression, and survival, partially by activating the MAPK/ERK pathway. Our findings partially elucidated the roles of LINC00978 in HCC carcinogenesis, and identified a therapeutic target for HCC.

Citing Articles

CDC25B Is a Prognostic Biomarker Associated With Immune Infiltration and Drug Sensitivity in Hepatocellular Carcinoma.

Huang Z, Xu L, Wu Z, Xiong X, Luo L, Wen Z Int J Genomics. 2024; 2024:8922878.

PMID: 39371450 PMC: 11455594. DOI: 10.1155/2024/8922878.

Biological Roles and Pathogenic Mechanisms of LncRNA MIR4435-2HG in Cancer: A Comprehensive Review.

Chen Z, Guan D, Zhu Q, Wang Z, Han F, Zhou W Curr Issues Mol Biol. 2023; 45(11):8864-8881.

PMID: 37998733 PMC: 10670187. DOI: 10.3390/cimb45110556.

Comparison of biological behavior of lacrimal gland adenoid cystic carcinoma with high-grade transformation cells.

Zhang C, Zhu L, Liu X, Jiang M, Lin T, He Y Int J Ophthalmol. 2023; 16(2):163-171.

PMID: 36816203 PMC: 9922631. DOI: 10.18240/ijo.2023.02.01.

Testis-specific protein Y-encoded 1 regulates androgen receptor expression through the MAPK/ERK pathway in male hepatocellular carcinoma.

Lu Z, Yang D, Qin S, Mo C, Zhang L, Ou Y Saudi Med J. 2022; 43(10):1087-1095.

PMID: 36261201 PMC: 9994500. DOI: 10.15537/smj.2022.43.10.20220455.

MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis.

Zhong C, Xie Z, Zeng L, Yuan C, Duan S Front Immunol. 2022; 13:855078.

PMID: 35784328 PMC: 9240468. DOI: 10.3389/fimmu.2022.855078.

References

Yang L, Tang Y, Xiong F, He Y, Wei F, Zhang S . LncRNAs regulate cancer metastasis via binding to functional proteins. Oncotarget. 2018; 9(1):1426-1443. PMC: 5787449. DOI: 10.18632/oncotarget.22840. View

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Long Y, Wang X, Youmans D, Cech T . How do lncRNAs regulate transcription?. Sci Adv. 2017; 3(9):eaao2110. PMC: 5617379. DOI: 10.1126/sciadv.aao2110. View

Richly H, Schultheis B, Adamietz I, Kupsch P, Grubert M, Hilger R . Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2008; 45(4):579-87. DOI: 10.1016/j.ejca.2008.10.039. View

Chu C, Spitale R, Chang H . Technologies to probe functions and mechanisms of long noncoding RNAs. Nat Struct Mol Biol. 2015; 22(1):29-35. DOI: 10.1038/nsmb.2921. View

Wang D, Sun Q, Wu J, Wang W, Yao G, Li T . A new Prenylated Flavonoid induces G0/G1 arrest and apoptosis through p38/JNK MAPK pathways in Human Hepatocellular Carcinoma cells. Sci Rep. 2017; 7(1):5736. PMC: 5515844. DOI: 10.1038/s41598-017-05955-0. View

Peng C, Hu W, Weng X, Tong R, Cheng S, Ding C . Over Expression of Long Non-Coding RNA PANDA Promotes Hepatocellular Carcinoma by Inhibiting Senescence Associated Inflammatory Factor IL8. Sci Rep. 2017; 7(1):4186. PMC: 5482898. DOI: 10.1038/s41598-017-04045-5. View

Huynh H, Nguyen T, Chow K, Tan P, Soo K, Tran E . Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003; 3:19. PMC: 317301. DOI: 10.1186/1471-230X-3-19. View

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

10.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

11.

Yang Q, Xu E, Dai J, Liu B, Han Z, Wu J . A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by resveratrol in lung cancer. Toxicol Appl Pharmacol. 2015; 285(2):79-88. DOI: 10.1016/j.taap.2015.04.003. View

12.

Zhang Y, Li Z, Zhang Y, Zhong Q, Chen Q, Zhang L . Molecular mechanism of HEIH and HULC in the proliferation and invasion of hepatoma cells. Int J Clin Exp Med. 2015; 8(8):12956-62. PMC: 4612899. View

13.

Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M . Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer. 2003; 97(12):3017-26. DOI: 10.1002/cncr.11425. View

14.

Llovet J, Fuster J, Bruix J . The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 Suppl 1):S115-20. DOI: 10.1002/lt.20034. View

15.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

16.

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

17.

Kikuchi K, Fukuda M, Ito T, Inoue M, Yokoi T, Chiku S . Transcripts of unknown function in multiple-signaling pathways involved in human stem cell differentiation. Nucleic Acids Res. 2009; 37(15):4987-5000. PMC: 2731886. DOI: 10.1093/nar/gkp426. View

18.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

19.

Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J . A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PLoS One. 2012; 7(4):e35145. PMC: 3320879. DOI: 10.1371/journal.pone.0035145. View

20.

Hsieh Y, Wu T, Huang C, Hsieh Y, Hwang J, Liu J . p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res. 2007; 67(9):4320-7. DOI: 10.1158/0008-5472.CAN-06-2486. View